358 related articles for article (PubMed ID: 24000164)
1. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
2. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
3. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
[TBL] [Abstract][Full Text] [Related]
4. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
Sekijima Y
Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
[TBL] [Abstract][Full Text] [Related]
5. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
6. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a case report].
Miyazaki Y
Nihon Ronen Igakkai Zasshi; 2017; 54(1):75-80. PubMed ID: 28202889
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
11. Tafamidis: a review of its use in familial amyloid polyneuropathy.
Scott LJ
Drugs; 2014 Aug; 74(12):1371-8. PubMed ID: 25022953
[TBL] [Abstract][Full Text] [Related]
12. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.
Lozeron P; Théaudin M; Mincheva Z; Ducot B; Lacroix C; Adams D;
Eur J Neurol; 2013 Dec; 20(12):1539-45. PubMed ID: 23834402
[TBL] [Abstract][Full Text] [Related]
13. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
14. Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer.
Cotrina EY; Oliveira Â; Leite JP; Llop J; Gales L; Quintana J; Cardoso I; Arsequell G
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998442
[TBL] [Abstract][Full Text] [Related]
15. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T; Maia LF; Martins da Silva A; Waddington Cruz M; Planté-Bordeneuve V; Lozeron P; Suhr OB; Campistol JM; Conceição IM; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Wilson A; Grogan DR
Neurology; 2012 Aug; 79(8):785-92. PubMed ID: 22843282
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
[TBL] [Abstract][Full Text] [Related]
17. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
[TBL] [Abstract][Full Text] [Related]
18. [Familial amyloid polyneuropathies: therapeutic issues].
Adams D; Cauquil C; Théaudin M
Bull Acad Natl Med; 2012 Oct; 196(7):1333-45; discussion 1345-7. PubMed ID: 23815018
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
[TBL] [Abstract][Full Text] [Related]
20. Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.
Li H; Zhang Y; Cao L; Xiong R; Zhang B; Wu L; Zhao Z; Chen SD
Drug Des Devel Ther; 2014; 8():2121-8. PubMed ID: 25382970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
